FDA approval provides an important option for those unable to take oral formulation of TPOXX
Shares are moving higher today by 30% in the pre-market on FDA approval of IV TPOXX for the treatment of small pox.
Shares are trading around $9.50 as I’m wiring this on more than 15,000 trades and 2.3 million plus shares and climbing.